1. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
- Author
-
Jeung L, Smits LMG, Hoogervorst ELJ, van Oosten BW, and Frequin STFM
- Subjects
- Adult, Brain diagnostic imaging, Humans, Magnetic Resonance Imaging, Male, Brain pathology, Fingolimod Hydrochloride adverse effects, Immunosuppressive Agents adverse effects, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis, Relapsing-Remitting pathology
- Abstract
A 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in longstanding MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the development of TDL under treatment with fingolimod, suggesting a causal relation., Competing Interests: Declaration of Competing Interest All of the authors report no conflicts of interest., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF